• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment.

作者信息

Song Yunlong, Fang Rongchao, Yu Bo

机构信息

Respiratory Intensive Care Unit, Tengzhou Central People's Hospital, Tengzhou, China.

出版信息

Intern Emerg Med. 2025 Jul 22. doi: 10.1007/s11739-025-04056-5.

DOI:10.1007/s11739-025-04056-5
PMID:40696249
Abstract
摘要

相似文献

1
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对2型糖尿病和代谢相关脂肪性肝病患者通过磁共振成像-质子密度脂肪分数（MRI-PDFF）检测的肝脂肪变性的影响：评论
Intern Emerg Med. 2025 Jul 22. doi: 10.1007/s11739-025-04056-5.
2
The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.MRI-PDFF对代谢功能障碍相关脂肪性肝病患者肝脂肪变性的诊断价值：一项系统评价和荟萃分析
BMC Gastroenterol. 2025 Jul 1;25(1):451. doi: 10.1186/s12876-025-04017-4.
3
Genetic variants influencing liver fat in normal-weight individuals of European ancestry.影响欧洲血统正常体重个体肝脏脂肪的基因变异。
JHEP Rep. 2025 May 14;7(8):101453. doi: 10.1016/j.jhepr.2025.101453. eCollection 2025 Aug.
4
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对2型糖尿病和代谢相关脂肪性肝病患者经磁共振成像-质子密度脂肪分数（MRI-PDFF）检测的肝脂肪变性的影响。
Intern Emerg Med. 2025 Jun;20(4):1025-1033. doi: 10.1007/s11739-025-03902-w. Epub 2025 Mar 14.
5
Ultrasound hepatorenal index for the diagnosis of steatosis in patients with type 2 diabetes: a prospective validation study.超声肝肾指数用于诊断2型糖尿病患者肝脂肪变性：一项前瞻性验证研究。
Eur Radiol. 2025 Jun 25. doi: 10.1007/s00330-025-11774-z.
6
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病和代谢相关脂肪性肝病患者通过磁共振成像-质子密度脂肪分数检测的肝脂肪变性的影响：评论
Intern Emerg Med. 2025 Jun 17. doi: 10.1007/s11739-025-04024-z.
7
In-vivo liver proton density fat fraction quantification at 0.55 T: a pilot study with comparison against 3 T MRI.0.55T下肝脏质子密度脂肪分数的活体定量：一项与3T MRI对比的初步研究。
MAGMA. 2025 Jul 15. doi: 10.1007/s10334-025-01277-9.
8
Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.普通人群中风险 MASH、MetALD 和酒精相关脂肪性肝病的流行情况。
Aliment Pharmacol Ther. 2024 May;59(10):1271-1281. doi: 10.1111/apt.17958. Epub 2024 Mar 19.
9
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis.减重干预可改善肥胖患者代谢功能障碍相关脂肪性肝炎：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Jul;30(3):561-576. doi: 10.3350/cmh.2023.0384. Epub 2024 Jun 3.
10
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.以基于磁共振成像的质子密度脂肪分数为参考标准，比较衰减成像与受控衰减参数对肝脂肪变性的诊断性能：一项前瞻性多中心研究。
J Gastroenterol. 2025 Jun;60(6):727-737. doi: 10.1007/s00535-025-02224-0. Epub 2025 Feb 24.

本文引用的文献

1
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对2型糖尿病和代谢相关脂肪性肝病患者经磁共振成像-质子密度脂肪分数（MRI-PDFF）检测的肝脂肪变性的影响。
Intern Emerg Med. 2025 Jun;20(4):1025-1033. doi: 10.1007/s11739-025-03902-w. Epub 2025 Mar 14.
2
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.恩格列净有效降低血糖控制良好的 2 型糖尿病患者的肝脏脂肪含量：一项随机、双盲、4 期、安慰剂对照试验。
Diabetes Care. 2020 Feb;43(2):298-305. doi: 10.2337/dc19-0641. Epub 2019 Sep 20.
3
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
恩格列净对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脏脂肪的影响：一项随机对照试验（E-LIFT 试验）。
Diabetes Care. 2018 Aug;41(8):1801-1808. doi: 10.2337/dc18-0165. Epub 2018 Jun 12.
4
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.非酒精性脂肪性肝病中纤维化阶段导致的死亡风险增加：系统评价与荟萃分析
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
5
Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis.体重减轻对非酒精性脂肪性肝炎患者肝脏脂肪和体积磁共振成像评估的影响。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):561-568.e1. doi: 10.1016/j.cgh.2014.08.039. Epub 2014 Sep 15.